Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 18/20 | 0.63 |
| ▸ | FLT4 | P35916 | 18/20 | 0.63 |
| ▸ | KDR | P35968 | 18/20 | 0.63 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.63 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4372082 | 0.90 | BCL2L1 (0.61) | FLT1FLT4KDRBCL2L1MCL1 | |
| SCHEMBL4378321 | 0.90 | BCL2L1 (0.61) | FLT1FLT4KDRBCL2L1MCL1 | |
| SCHEMBL4371085 | 0.90 | MCL1 (0.61) | FLT1FLT4KDRBCL2L1MCL1 | |
| SCHEMBL4371380 | 0.90 | BCL2L1 (0.59) | FLT1FLT4KDRBCL2L1MCL1 | |
| SCHEMBL4374669 | 0.90 | BCL2L1 (0.59) | FLT1FLT4KDRBCL2L1MCL1 | |
| SCHEMBL4374214 | 0.81 | BCL2L1 (0.56) | FLT1FLT4KDRBCL2L1MCL1 | |
| SCHEMBL4372151 | 0.81 | BCL2L1 (0.46) | FLT1FLT4KDRBCL2L1MCL1 | |
| SCHEMBL1207429 | 0.81 | FLT1 (0.72) | FLT1FLT4KDR | |
| SCHEMBL1882029 | 0.81 | FLT1 (0.72) | FLT1FLT4KDR | |
| SCHEMBL1882024 | 0.79 | FLT1 (0.71) | FLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960361-A1 | PYRIDYLSULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTINEOPLASTIC AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-27 | — | — | EP | claimed |
| WO-2007059872-A1 | PYRIDYLSULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTINEOPLASTIC AGENTS | F. HOFFMNN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | claimed |
| US-20070123513-A1 | 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent | HOFFMANN-LA ROCHE INC. | 2007-05-31 | — | — | US | claimed |
| US-7625896-B2 | Pyridylsulfonamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1960361-A1 | PYRIDYLSULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTINEOPLASTIC AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007059872-A1 | PYRIDYLSULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTINEOPLASTIC AGENTS | F. HOFFMNN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | disclosed |
| US-20070123513-A1 | 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent | HOFFMANN-LA ROCHE INC. | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123513-A1 | 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent | TPMT, BPNT1, SLC6A3 | FLT1 4752/4885FLT4 4294/4885KDR 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.